FreeGulliver LLC’s Novo Nordisk NVO Stock Holding History

FreeGulliver LLC’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-43,000	Closed	-$2.99M	–	93
2025 Q1	$2.99M	Buy	43,000 +1,000	+2%	+$82.6K	1.47%	13
2024 Q4	$3.61M	Buy	+42,000	New	+$4.54M	1.72%	15

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

FreeGulliver LLC's NVO Position: Q2 2025 in Review

FreeGulliver LLC sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 1 share — an estimated $69 sold.

FreeGulliver LLC first reported a position in NVO in Q4 2024 and held it in 2 quarters. The position peaked at $13.1K in Q4 2024. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

FreeGulliver LLC reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
FreeGulliver LLC sold 1 Novo Nordisk share in Q2 2025, an estimated $69.
FreeGulliver LLC first reported a position in Novo Nordisk in Q4 2024 and held it in 2 quarters.
FreeGulliver LLC's Novo Nordisk position peaked at $13.1K in Q4 2024.
1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on FreeGulliver LLC's 13F filing for Q2 2025, filed 12 Aug 2025.